1. Home
  2. SKYE vs XWEL Comparison

SKYE vs XWEL Comparison

Compare SKYE & XWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

XWEL

XWELL Inc.

N/A

Current Price

$0.53

Market Cap

5.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
XWEL
Founded
2012
2006
Country
United States
United States
Employees
N/A
280
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.9M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
SKYE
XWEL
Price
$1.18
$0.53
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $68.00
N/A
AVG Volume (30 Days)
★ 98.4K
33.4K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $29,210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.26
$0.26
52 Week High
$11.68
$2.20

Technical Indicators

Market Signals
Indicator
SKYE
XWEL
Relative Strength Index (RSI) 44.62 33.71
Support Level $0.26 $0.33
Resistance Level $1.66 $0.96
Average True Range (ATR) 0.20 0.05
MACD -0.00 -0.00
Stochastic Oscillator 62.05 21.55

Price Performance

Historical Comparison
SKYE
XWEL

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About XWEL XWELL Inc.

XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.

Share on Social Networks: